Clinical Trials
22 trialsNCT04285567 2026-03-03
CRISTALLO
Hoffmann-La Roche
Phase 3 Completed
NCT01776840 2025-07-08
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT00769522 2024-12-31
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 3 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT00991211 2024-08-22
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
Phase 3 Completed
NCT01456351 2024-08-22
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
University of Giessen
Phase 3 Completed
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT02005471 2023-10-17
MURANO
Hoffmann-La Roche
Phase 3 Completed
NCT01596621 2023-05-26
A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT01332968 2022-08-11
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
Phase 3 Completed
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT01889069 2020-08-13
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Hoffmann-La Roche
Phase 3 Completed
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT01611090 2020-03-03
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01059630 2020-01-13
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc.
Phase 3 Completed
NCT01905943 2019-10-28
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT00877006 2018-02-05
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT01724021 2018-01-23
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
Phase 3 Completed
NCT01500083 2017-08-14
BENDACT
Lundbeck Canada Inc.
Phase 3 Completed
NCT00139841 2014-05-09
Safety and Efficacy of Treandaâ„¢ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT01073163 2014-04-24
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed